Summary:
PHASE 1B, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO DETERMINE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF DNL201 IN SUBJECTS WITH PARKINSON’S DISEASE
Qualified Participants Must:
Subjects aged 30-75 years, with a clinical diagnosis of Parkinson's disease
Qualified Participants May Receive:
Compensation for time and travel